Serum and urinary levels of CD222 in cancer: origin and diagnostic value.

In this study, we analysed the level of CD222 present in body fluids, namely in serum and urine, of cancer patients. We found significantly elevated levels of soluble CD222 in sera of cancer patients compared to healthy controls irrespective of the type of disease. The urine CD222 levels were increased specifically in breast cancer and multiple myeloma. In contrast to serum, CD222 was present within CD222-positive exosomes in urine pointing to different origins of CD222 present in various human body fluids. Based on this work, we propose serum soluble CD222 as a general biomarker for tumorigenesis. PMID: 29940770 [PubMed - as supplied by publisher]
Source: Neoplasma - Category: Cancer & Oncology Authors: Tags: Neoplasma Source Type: research